targin forðatafla 10 mg /5 mg
mundipharma a/s - oxycodonum hýdróklóríð; naloxonum hýdróklóríð - forðatafla - 10 mg /5 mg
targin forðatafla 20 mg /10 mg
mundipharma a/s - oxycodonum hýdróklóríð; naloxonum hýdróklóríð - forðatafla - 20 mg /10 mg
targin forðatafla 40 mg/20 mg
mundipharma a/s - oxycodonum hýdróklóríð; naloxonum hýdróklóríð - forðatafla - 40 mg/20 mg
targin forðatafla 5 mg/2,5 mg
mundipharma a/s - oxycodonum hýdróklóríð; naloxonum hýdróklóríð - forðatafla - 5 mg/2,5 mg
nicorette (lyfjaver) munnholsúði, lausn 1 mg/skammt
lyfjaver ehf. - nicotinum - munnholsúði, lausn - 1 mg/skammt
nicorette quickmist munnholsúði, lausn 1 mg/skammt
mcneil denmark aps - nicotinum - munnholsúði, lausn - 1 mg/skammt
nicorette quickmist cool berry munnholsúði, lausn 1 mg/skammt
mcneil denmark aps - nicotinum - munnholsúði, lausn - 1 mg/skammt
exagon vet. (exagon 400) stungulyf, lausn 400 mg/ml
vetviva richter gmbh - pentobarbitalum natríum - stungulyf, lausn - 400 mg/ml
brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - Æxlishemjandi lyf - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).
tricaine pharmaq (ms222 pharmaq) baðduft til meðhöndlunar fiska, lausn 1000 mg/g
pharmaq as - tricaine methane sulfonate - baðduft til meðhöndlunar fiska, lausn - 1000 mg/g